Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Soluble CD30: A Possible Serum Tumor Marker for Primary Effusion Lymphoma

  • Michai, Manthana (Division of Hematopoiesis, Center for AIDS Research, Kumamoto University) ;
  • Goto, Hiroki (Division of Hematopoiesis, Center for AIDS Research, Kumamoto University) ;
  • Hattori, Shinichiro (Division of Hematopoiesis, Center for AIDS Research, Kumamoto University) ;
  • Vaeteewoottacharn, Kulthida (Division of Hematopoiesis, Center for AIDS Research, Kumamoto University) ;
  • Wongkham, Chaisiri (Department of Biochemistry, Faculty of Medicine, Khon Kaen University) ;
  • Wongkham, Sopit (Department of Biochemistry, Faculty of Medicine, Khon Kaen University) ;
  • Okada, Seiji (Division of Hematopoiesis, Center for AIDS Research, Kumamoto University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The serum level of soluble CD30 (sCD30) is known to be increased with several lymphomas and to correlate with prognosis. Primary effusion lymphoma (PEL) is a highly aggressive malignant lymphoma with poor prognosis, but the existence and significance of sCD30 in PEL have not yet been investigated in detail. Objectives: Since the membrane type of CD30 is frequently expressed on the surface of PEL cells, we compared the expression of the membrane type of CD30 and the production of sCD30 among PEL cell lines as well as other lymphomas. Methods: The expression of surface CD30 in various lymphoma cell lines was analyzed with flow cytometry ans sCD30 was quantified by ELISA. Results: Both surface and sCD30 were detected on PEL cell lines as well as on Hodgkin's lymphoma and adult T-cell leukemia/lymphoma cell lines. Surface CD30 and sCD30 levels of each cell lines correlated with each other. Conclusion: The serum level of sCD30 appear to be a useful biological tumor marker for the diagnosis and management of CD30-positive PEL.

Keywords

References

  1. Al-Shamkhani A (2004). The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol, 4, 355-9. https://doi.org/10.1016/j.coph.2004.02.007
  2. Ambinder RF, Bhatia K, Martinez-Maza O, et al (2010). Cancer biomarkers in HIV patients. Curr Opin HIV AIDS, 5, 531-7. https://doi.org/10.1097/COH.0b013e32833f327e
  3. Breen EC, Fatahi S, Epeldegui M, et al (2006). Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol, 27, 187-94. https://doi.org/10.1159/000093022
  4. Chen YB, Rahemtullah A, Hochberg E (2007). Primary effusion lymphoma. Oncol, 12, 569-76. https://doi.org/10.1634/theoncologist.12-5-569
  5. Drexler HG, Uphoff CC, Gaidano G, et al (1998). Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia, 12, 1507-17. https://doi.org/10.1038/sj.leu.2401160
  6. Higuchi M, Matsuda T, Mori N, et al (2005). Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirology, 2, 29. https://doi.org/10.1186/1742-4690-2-29
  7. Horie R, Watanabe T (1998). CD30: expression and function in health and disease. Semin Immunol, 10, 457-70. https://doi.org/10.1006/smim.1998.0156
  8. Jarrin I, Boval B, Mazeron MC, et al (2011). Can serum soluble CD23 OR CD30 predict the occurence of lymphoma in HIVinfected patients? J Acquir Immune Defic Syndr, 57, 58-61. https://doi.org/10.1097/QAI.0b013e31821dbbcf
  9. Katano H, Hoshino Y, Morishita Y, et al (1999). Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol, 58, 394-401. https://doi.org/10.1002/(SICI)1096-9071(199908)58:4<394::AID-JMV12>3.0.CO;2-H
  10. Miyagi J, Masuda M, Takasu N, et al (2002). Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice. Int J Hematol, 76, 165-72.
  11. Nadali G, Vinante F, Ambrosetti A, et al (1994). Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol, 12, 793-7.
  12. Nadali G, Vinante F, Stein H, et al (1995). Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol, 13, 1355-60.
  13. Nador RG, Cesarman E, Chadburn A, et al (1996). Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood, 88, 645-56
  14. Nagai H, Iwasaki N, Odawara T, et al (2008). Actual status of AIDS-related lymphoma management in Japan. Int J Hematol, 87, 442-3 https://doi.org/10.1007/s12185-008-0073-8
  15. Nishioka C, Takemoto S, Kataoka S, et al (2005). Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci, 96, 810-5. https://doi.org/10.1111/j.1349-7006.2005.00106.x
  16. Purdue MP, Lan Q, Martinez-Maza O, et al (2009). A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood, 114, 2730-2. https://doi.org/10.1182/blood-2009-04-217521
  17. Vermeulen R, Hosnijeh FS, Portengen L, et al (2011). Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev, 20, 1925-7. https://doi.org/10.1158/1055-9965.EPI-11-0396
  18. Visco C, Nadali G, Vassilakopoulos TP, et al (2006). Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol, 77, 387-94. https://doi.org/10.1111/j.1600-0609.2006.00725.x

Cited by

  1. Hippuristanol Reduces the Viability of Primary Effusion Lymphoma Cells both in Vitro and in Vivo vol.11, pp.9, 2013, https://doi.org/10.3390/md11093410
  2. Current status of treatment for primary effusion lymphoma vol.3, pp.3, 2014, https://doi.org/10.5582/irdr.2014.01010
  3. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses vol.138, pp.10, 2016, https://doi.org/10.1002/ijc.29969
  4. Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8253
  5. An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature vol.6, pp.4, 2013, https://doi.org/10.3892/ol.2013.1501
  6. In vitro and in vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida vol.38, pp.5, 2017, https://doi.org/10.3892/or.2017.5978